TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Zoetis (ZTS) , an animal health company, is well run. The company was spun off from Pfizer (PFE) , which Cramer says unlocked plenty of value for investors, but said it would have been better if Pfizer kept Zoetis. On Wednesday, Zoetis reported better than expected third quarter earnings on both the top and bottom lines. Revenue rose 2% year over year to $1.24 billion. It also raised its adjusted earnings guidance for the year.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.